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Renal replacement therapy after repair of 
congenital heart disease in children 
A comparison of hemofiltration and peritoneal dialysis 
The development of renal failure necessitating peritoneal dialysis after cardiac operations i associated 
with a reported mortality greater than 50%. Improved fluid removal and nutritional support have been 
reported with the use of continuous arteriovenous hemofiltration and continuous venovenous hemofil- 
tration techniques. We have compared our experience with all three techniques in managing children who 
required renal replacement therapy after cardiac operations in terms of efficacy (fluid removal, calorie 
intake, and clearance of urea and creatinine), complications, and outcome. Over a 5-year period renal 
replacement therapy was initiated in 42 children, and in 34 of them it was successfully established for 
more than a 24-hour period: 17 were managed with peritoneal dialysis, 8 with continuous arteriovenous 
hemofiltration, and 9 with continuous venovenous hemofiltration. A net negative fluid balance was 
achieved in only 6 (35%) patients treated with peritoneal dialysis compared with 50% of those treated with 
continuous venovenous hemofiltration and 89% of those treated with continuous venovenous hemofil- 
tration. In terms of nutritional support, calorie intake increased by 43% after peritoneal dialysis was 
started compared with 515% and 409% in the arteriovenous and venovenous hemofiltration groups, 
respectively, (p< 0.005). The serum urea levels fell by 36% (p = 0.02) and 39% (p = 0.005) compared with 
pre-therapy levels with arteriovenous and venovenous hemofiltration, respectively, and the creatinine 
content was reduced by 19% and 33% (p = 0.003). Neither parameter was reduced in the peritoneal 
dialysis group. We conclude that the use of hemofiltration as a renal replacement therapy after surgical 
correction of congenital heart disease offers significant advantages over the more traditional approach of 
peritoneal dialysis. In addition, we suggest that a more aggressive approach to the management of fluid 
overload and nutritional depletion with hemofiltration may result in a decrease in the very high mortality 
seen in renal failure after cardiac operations. (J TrIORAC CARDIOVASC SURG 1995;109:322-31) 
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R.ena l  insufficiency after cardiac operations in 
children as manifested by oliguria and a positive 
fluid balance is relatively common. Although in 
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most instances the situation resolves with the use of 
diuretic therapy and inotropic support, if it does not, 
the resulting fluid overload together with the limi- 
tations placed on free water intake leads to severe 
restriction of nutritional support, hypervolemia, nd 
electrolyte disturbances. The excess tissue and lung 
edema may also impede pulmonary gas exchange 
and postpone weaning from mechanical ventilation. 
Persisting oliguria accompanied by a rising creati- 
nine concentration that cannot be reversed with 
diuretic therapy is an indication for renal replace- 
ment therapy in the form of either peritoneal dial- 
ysis (PD) or hemodialysis. In various series the rate 
of intervention with renal replacement therapy has 
been between 1.6% and 7.7% in patients who have 
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had cardiotomy, with an overall survival of less than 
50%. 1-9 PD has long been established as the primary 
form of renal replacement therapy after cardiac 
operations.l-s, lo-~3 Far less experience with the use 
of short-term hemodialysis n this situation has been 
reported, apart from a single series of 11 patients 
with only a 30% survival. 14 Neither of these modal- 
ities is entirely satisfactory. In the case of PD, it can 
be difficult to achieve a satisfactory negative fluid 
balance, even with a surgically placed Tenckhoff 
catheter (Accurate Surgical Instruments Corp., To- 
ronto, Ontario, Canada), because of either leakage 
around the insertion site or inadequate peritoneal 
perfusion, whereas hemodialysis can remove fluid 
only on an intermittent basis and not infrequently 
results in hemodynamic nstability. More recently, 
continuous hemofiltration modalities for renal re- 
placement therapy have been used in preference to 
both PD and intermittent hemodialysis in acute 
renal failure of various origins. The most commonly 
used technique, continuous arteriovenous hemofil- 
tration (CAVH), was first introduced into clinical 
use by Kramer and associates 15in 1977 as a system 
allowing for fluid and electrolyte correction. Several 
series have now been published that show that 
CAVH can successfully achieve a negative fluid 
balance in critically ill children with acute renal 
failure. 16-24 In continuous venovenous hemofiltra- 
tion (CVVH), on the other hand, a double-lumen 
venous catheter is used and replaces the need for 
arterial access, and a roller pump is placed between 
the afferent venous line and the filter to provide the 
necessary driving pressure. Although CVVH has 
been in clinical use since the early 1980s, the first 
published series of patients managed with CVVH 
appeared in 1988. 25 As with CAVH, the techniques 
and principles of CVVH also lent themselves to the 
management of acute renal failure in the pediatric 
intensive care unit (ICU), and increasing experience 
has now been gained in the use of the technique in 
a variety of conditions giving rise to acute renal 
failure. 26-29 
In an attempt o determine the optimal manage- 
ment of patients with acute renal failure after car- 
diopulmonary bypass, we have undertaken a retro- 
spective review of our experience with PD and 
CAVH, which were used before the introduction of 
CVVH, and compared it with a prospective series of 
patients treated with CVVH during the past 5 years 
in the Pediatric Intensive Care Unit at the Hospital 
for Sick Children. In particular we focused our 
review on fluid and electrolyte balance, caloric 
intake, and cost and complications of therapy. 
Patients and methods 
Data were collected retrospectively for all patients 
managed with PD and CAVH after cardiac operations 
and prospectively for the CVVH group. In all cases the 
indications for renal replacement therapy included one or 
more of the following: (1) anuria or oliguria (urine output 
<0.5 ml/kg per hour) for 12 hours or more, (2) fluid 
overload with tissue edema not responsive to diuretic 
therapy, (3) hyperkalemia (potassium concentration >5 
mmol/L), and (4) the necessity for intravenous nutrition in 
the presence of decreased renal function and positive fluid 
balance. 
Demographic data collected included age, weight, and 
sex. The clinical condition of each patient, including the 
need for mechanical ventilation or inotropic support, 
hemodynamic stability, and other organ system failure, 
was recorded. Caloric intake and daily fluid balance were 
recorded before the start of renal replacement therapy 
and for up to 3 days after the initiation of therapy, as were 
biochemical parameters including urea, creatinine, potas- 
sium, and phosphate concentrations. In addition, note was 
made daily of any fluctuations in the patients' core 
temperatures (rectal or esophageal) and of the complete 
blood count. 
Once initiated, the success or failure of renal replace- 
ment therapy was evaluated on the basis of (1) fluid 
removal, (2) electrolyte status, (3) change in serum creat- 
inine and urea concentration, (4) caloric intake compared 
before and after initiation of renal replacement therapy, 
(5) complications related to renal replacement therapy, 
and (6) clinical outcome. In addition, in patients treated 
by either CAVH or CVVH, note was made of the number 
of filter changes necessary and the resulting cost per 
patient day. 
PD. PD was performed after surgical placement of a 
tunneled Tenckhoff catheter or a Cook pediatric PD 
catheter (Cook Group Co., Bloomington, Ind.) and at- 
tachment to dialysis tubing (Travenol Inc., Mississauga, 
Ontario, Canada). The dialysate fluid used was Dianeal 
solution, 1.5% to 4.25% (Baxter Healthcare Corp., Deer- 
field, Ill.), to which heparin and cefazolin were added. 
Volumes of dialysate ranged from 10 ml/kg to 30 ml/kg, 
with dwell times of 30 minutes to 2 hours. Potassium or 
sodium bicarbonate was added to the Dianeal solution 
when warranted on the basis of the biochemical profile of 
the individual patient. PD was managed by the nephrology 
staff in conjunction with the pediatric ICU staff, who were 
ultimately responsible for overall fluid management and 
nutritional control for the patient. The pediatric ICU 
nursing staff assumed responsibility for the day to day 
operation of the PD system. The principles and practice 
governing PD have been reviewed elsewhere. 1° 
Technical principles of hemofiltration. Hemofiltration is 
an extracorporeal form of renal replacement therapy that 
uses convection rather than diffusive transport for solute 
and fluid removal. The flow of ultrafiltrate fluid through 
the highly permeable hemofilter is governed by a hydro- 
static pressure gradient. In the case of CAVH this is 
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Table I. Guidefines for blood flow and predilution 
fluid flow for CVVH 
Maximum 
Blood Predilution ultrafiltrate 
Weight flow flow removal 
(kg) (ml/min) (ml/hr) (ml/hr) 
<10 50 200-400 750 
10-20 80 300-650 1200 
>20 150 600-1000 2250 
arterial minus venous pressure; a mean arterial pressure 
of 50 to 60 mm Hg is considered necessary to provide 
adequate hydrostatic pressure. In CVVH the pressure 
gradient across the filter is generated by the pumping 
mechanism. The volume of ultrafiltrate in either system 
can be controlled by altering the pressure in the ultrafil- 
trate line by passing the tubing through a gravimetric 
pump set to restrict he flow at a preselected rate. Plasma 
ultrafiltrate removal is balanced by a combination of a 
predilution electrolyte solution and intravenous alimenta- 
tion fluid. A detailed account of the CAVH principles and 
technique used in the management of patients with con- 
genital heart disease has recently been published. 16 Arte- 
rial and venous vascular access was established and the 
cannulas were connected to hemofiltration tubing placed 
in line with the hemofilter. Dianeal 0.5% solution was 
used as a predilution replacement fluid and anticoagula- 
tion was maintained with heparin. 
CVVH system. The principles of CVVH in critically ill 
patients have been reviewed elsewhere) ° The circuit in 
this instance was primed with a heparin-containing saline 
solution (5000 units/L), which was then rinsed out. The 
final prime was either blood or saline depending on 
patient size. Vascular access was obtained to a major vein 
(femoral, internal jugular, subclavian) via a percutaneous 
Seldinger technique, with the alternative route of a surgi- 
cal cutdown used when the Seldinger technique failed. 
Either a Vascath (Vascath Inc., Mississauga, Ontario, 
Canada) or Quinton (Quinton Instrument Co., Seattle, 
Wash.) double-lumen cannula of appropriate size for 
patient age and weight was placed. The cannula was 
connected to hemofiltration tubing (Hospal, Basel, Swit- 
zerland). The venous inflow through the "arterial" lumen 
was passed to a roller pump (BSM 22, Hospal). An 
intravenous electrolyte solution (0.5% Dianeal solution) 
was introduced as a predilution fluid connected to the 
circuit proximal to the pump. The amount of predilution 
fluid used depended on the patient's weight (Table I), 
with the limitation that the total should not be allowed to 
exceed 14% of the blood flow to the filter. Occasionally 
the clinical and biochemical profile of the patient neces- 
sitated the addition of potassium or bicarbonate to the 
predilution fluid. In the presence of a persistent metabolic 
acidosis the predilution fluid was changed to a bicarbon- 
ate/electrolyte solution. After the pump and before the 
filter, a second port in the inflow tubing allowed admin- 
istration of a continuous infusion of heparin at a dose of 
10 to 20 units/kg per hour. The anticoagulation of the 
system was monitored by the activated clotting time 
(Hemochron, International Technidyne Corporation, 
Edison, N.J.). Activated clotting times were generally 
maintained in the range of 150 to 180 seconds. The dose 
of heparin used to keep the activated clotting times in this 
range varied from none (bleeding diatheses, coagulopa- 
thies) to 20 units/kg per hour. Blood then passed through 
the hemofilter: Amicon diafilter 20 (Amicon division, WR 
Grace and Co., Beverly, Mass), Fresenius 40 (Fresenius, 
Bad Homburg, Germany), or CT 110 HG (Baxter Health- 
care Ltd., Mississauga, Ontario, Canada). The amount of 
ultrafiltrate removed was regulated by a gravimetric pump 
(IVAC Corporation, San Diego, Calif.) attached to a side 
port of the flter. The amount of ultrafiltrate removed was 
based on the fluid balance status and stability of an 
individual patient. In addition, we adhered to the principle 
common to all hemofiltration systems that ultrafiltrate 
removal should not be allowed to exceed 25% of the blood 
flow to the filter, inasmuch as the negative pressure 
required to generate this amount of fluid would disrupt 
the filter. In practice, the amount of ultrafiltrate removal 
never approaches this level. The blood flow guidelines and 
predilution flows used are listed in Table I. 
Blood returning to the patient after the filter via the 
"venous" lumen of the catheter passed through a drip 
chamber with an air bubble detector and finally a blood 
warmer (Hotline, Level 1 Technologies Inc., Rockland, 
Mass.). A pressure alarm detected increased venous re- 
sistance in the circuit. Once the system was connected to 
the patient, maintenance of the system was under the 
control of the bedside nurse and did not require special- 
ized dialysis taff. Fluid balance was monitored hourly. All 
fluids added to or removed from the system were con- 
trolled by infusion pumps. The electrolyte status was 
monitored on a 4- to 6-hour basis. Urea, creatinine, and 
complete blood counts were routinely monitored twice a 
day. 
Statistical analysis. Data are reported as mean plus or 
minus standard error of the mean. For each form of renal 
replacement therapy, pretreatment and posttreatment 
values were compared by means of Student's paired t test. 
Multiple comparisons were performed by analysis of 
variance. Intergroup comparisons were made with Tukey's 
studentized range tests when a significant F value was 
obtained. A p value less than 0.05 was accepted as 
statistically significant. 
Results 
The charts of all patients managed with renal 
replacement therapy after cardiopulmonary bypass 
between July 1988 and December 1992 were re- 
viewed. Twenty-four patients had PD and nine 
patients were managed with CAVH.  Data on the 
management of PD were incomplete in three pa- 
tients and these were excluded. From July 1991 to 
December 1992, data were collected prospectively 
for the 12 patients who underwent CVVH. All 42 
patients underwent cardiac surgical procedures ne- 
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cessitating cardiopulmonary bypass and aortic cross- 
clamping. CAVH and CVVH were instituted in one 
patient each when PD failed. Demographic data 
from the three treatment groups are presented in 
Table II. The mortality rates were similar for the 
three groups with a range of 58% to 67%. All but 
one of the surviving patients had return of normal 
renal function, broadly defined as a normal urea and 
creatinine values and adequate urine output on 
discharge from the pediatric ICU. 
The time from the end of operation to the initia- 
tion of renal replacement therapy varied widely. The 
PD group had a mean time from surgery to initia- 
tion of dialysis of 2.5 days, with a range of 1 to 6 
days. This interval was increased in the CAVH and 
CVVH groups to a mean of 10 days and 6.7 days, 
respectively. In both hemofiltration groups four 
patients began having renal replacement therapy 
more than 7 days after the operation. The duration 
of treatment also varied widely depending on the 
mode of renal replacement therapy. In the CAVH 
group the mean duration of therapy was 57 hours, 
whereas in the PD and CVVH groups the mean 
durations of therapy were longer, at 136 and 168 
hours, respectively. 
The percentage of patients requiring a second 
surgical procedure was similar in all three groups, 
ranging from 33% to 42% (see Table II). All but 
three patients were receiving inotropic support and 
86% were receiving two cardiac support drugs or 
more in an attempt to maintain cardiovascular sta- 
bility. Dopamine and/or dobutamine were the first- 
line inotropic agents in all patients managed with 
renal replacement therapy (Tables IIIA and IIIB). 
Sepsis was suspected or proved before the initiation 
of renal replacement therapy in 18 patients (42%) 
and tended to be more prevalent in the patients 
treated with hemofiltration. Sepsis refers to the 
presence of a positive blood culture or the noting in 
the charts by the medical staff of the impression of 
sepsis (based on a combination of hemodynamic 
instability, hyperthermia, elevated or depressed neu- 
trophil count with leftward shift, and thrombocyto- 
penia). 
Only those patients who successfully underwent a 
form of renal replacement therapy for more than 24 
hours were analyzed with respect o fluid balance, 
caloric intake, biochemical analysis, and complica- 
tions attributable to the renal replacement therapy. 
They comprised 17 of 21 patients in the PD group, 
8 of 9 patients in the CAVH group, and 9 of 12 
Table II. Demographic data for each group 
PD CA VH C VVH 
(n = 21) (n = 9) (n = 12) 
Sex 13 M:8 F 5 M:4 F 7 M:5 F 
Age (yr) 
Mean 1.39 2.94 2.13 
Range 1 wk-ll yr 1 mo-9 yr 1 wk-5.3 yr 
Weight (kg) 
Mean 6.71 11.43 9.23 
Range 1.63-26.9 2.9-20.9 3.0-15 
Preexisting renal disease 0 3 0 
Survival 8 (38%) 3 (33%) 5 (42%) 
Normal renal function in 8 (100%) 2 (67%) 5 (100%) 
survivors 
Time postop (days) 
Mean 2.5 10 6.7 
Range 1-6 2-30 2-16 
Duration (hr) 
Mean 136 57 168 
Range 4-360 2-172 14-312 
Second surgical proce- 7 (33%) 3 (33%) 5 (42%) 
dure 
Inotropic agents* 19 (90%) 9 (100%) 12 (100%) 
Mechanical ventilation 21 (100%) 9 (100%) 12 (100%) 
Sepsis 6 (28%) 5 (55%) 7 (58%) 
*Patients receiving infusions of dopamine, pinephrine, and dobutamine, 
either singly or in combination. 
patients in the CVVH group. The remaining 8 
patients either died within 24 hours of the start of 
therapy or had recovery of renal function sufficient 
to allow the renal replacement therapy to be discon- 
tinued. In no case was the use of renal replacement 
therapy considered to be a contributary factor in the 
cause of death. 
The fluid balances were compared between the 
groups on the basis of the net negative fluid balance 
achieved over the first 3 days of renal replacement 
therapy. In the PD group, 6 of the 17 patients (35%) 
achieved a net negative fluid balance. The average 
fluid deficit was 9.2 ml/hr, with a range of 3.5 to 26 
ml/hr. Four of 8 patients (50%) in the CAVH group 
had a net negative fluid balance, with an average 
fluid deficit to 23 ml/hr (range 3.9 to 34 ml/hr). 
Finally, 8 of 9 (89%) patients treated with CVVH 
reached net negative fluid balances, with an average 
deficit of 17.7 ml/hr (range 3.6 to 35 ml/hr). 
Nutritional status was assessed by recording ca- 
loric intake for 24 hours immediately before the 
institution of renal replacement therapy and then 
daily for the first 3 days of treatment. The posttreat- 
ment values were obtained by averaging the values 
for these 3 days. Similar data acquisition and calcu- 
lations were undertaken for serum urea and creati- 
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Table IIIA. Details of age, lesion operation, inotropic support, type of RRT, and access site for patients 
undergoing hemofiltration 
Cardiac Inotropic drugs Type of Access 
Age lesion Operation ( pg/kg/min ) RR T site 
9 yr Pulm. atresia, VSD, AS Closure VSD, replacement ho- DOP 20/EPI 2 CAVH FA/FV 
mograft, aortic valvotomy 
1.8 yr TGA, DILV, PS, VSD Fontan DOP 5/AMR 5/EPI 10 CAVH FA/FV 
N VSD, coarctation Repair coarctation, closure VSD DOP 10/DOB 12.5 CAVH FA/FV 
N VSD, aortic atresia Repair coarctation, closure VSD DOP 20/EPI 1.2/NOR 0.5 CAVH FA/FV 
4 yr Pulm. atresia, VSD Conduit replacement, repair VSD DOP 2.5 CAVH FA/FV 
3 yr Tetralogy, AVSD Repair AVSD, RV-PA conduit DOP 5/AMR 20/EPI 0.5 CAVH FA/FV 
7 yr Tetralogy, AVSD Repair, closure residual VSD DOP 10/EPI 1.0 CAVH FA/FV 
1.3 yr PS, VSD, PA sling Pulm. valvotomy, closure VSD, DOP 20 CAVH FA/FV 
tracheal resection 
3 yr Pulm. atresia, VSD, single Closure VSD, RV-PA conduit, DOP 20/EPI 0.8 CAVH FA/FV 
coronary RPA repair 
N DILV, TGA, VSD Arterial switch, PA band DOP 10/DOB 20/EPI 0.3 CVVH FV 
N TGA, IVS Arterial switch DOP 10/EPI 1.8 CWH IJV 
N TGA, IVS Arterial switch DOP 20/EPI 1.2/NOR 1.2 CVVH FV 
6 mo Anomalous coronary Reimplantation DOB 10/EPI 0.6 CVVH FV 
5 yr Tetralogy Repair DOB 10/EPI 0.5/NOR 0.1 CVVH FV 
3.5 yr Pulm. atresia, VSD, AP RV-PA conduit, VSD repair DOP 15/EPI 0.5/NOR 0.4 CVVH IJV 
collaterals 
2 yr DORV Fontan DOP 10/ISP 0.15 CVVH FV 
N AVSD PA band DOP 10/DOB 20/EPI 0.1 CVVH FV 
4.5 yr DORV, PS Biventricular repair DOP 10/EPI 0.4 CVVH FV 
3 yr Tetralogy, AVSD Repair Glenn shunt DOP 15/EPI 0.1 CVVH IJV 
9 mo Tetralogy Repair DOP 15 CVVH IJV 
4.5 yr PS, VSD Fontan DOP 20 CVVH IJV 
RRT, Renal replacement therapy; VSD, ventricular septal defect; AS, aortic stenosis; TGA, transposition of the great arteries; DILV, double-inlet left 
ventricle; PS, pulmonary stenosis; AVSD, atrioventricular septal defect; PA, pulmonary artery;/VS, intact ventricular septum; AP, aortopulmonary; DORV, 
double-outlet right ventricle; RV, right ventricle; RPA, right pulmonary artery; DOB, dobutamine; EPI, epinephrine; AMR, amrinone; DOB, dobutamine; 
NOR, norepinephrine; ISP, isoproterenol; FA, femoral artery; FV, femoral vein; IJV,, internal jugular vein; N, newborn. 
nine values. The pretreatment and posttreatment 
values for each of the groups with respect o these 
parameters are presented in Table IV. The percent 
change from baseline for each group is given, as well 
as being depicted graphically in Figs. 1 and 2. 
The caloric intake was spectacularly better in the 
hemofiltration groups than in the PD group. In all 
three groups the caloric intake before renal replace- 
ment therapy was extremely low, ranging from a 
mean of 13.5 Kcal/kg per day for the CAVH group 
to 24.2 Kcal/kg per day for the PD group. There was 
no significant difference between the groups before 
institution of renal support (p = 0.09). After treat- 
ment was begun, the caloric intake improved in all 
patient groups: in the PD group caloric intake 
increased by 43% to 34 Kcal/kg per day (p = 0.01), 
in the CAVH group by 515% to 80 Kcal/kg per day 
(p = 0.003), and in the CVVH group by 409% to 76 
Kcal/kg per day (p < 0.0001). There was a much 
larger caloric increase in the hemofiltration groups 
than in the PD group (CAVHp < 0.05; CVVHp < 
0.05), whereas no significant difference was found 
when the two forms of hemofiltration were com- 
pared. 
Clearance of urea and creatinine was much more 
efficient with hemofiltration than with PD. No sta- 
tistical difference xisted among the three groups 
before institution of therapy for either urea (p = 
0.13) or creatinine (p = 0.62). Both hemofiltration 
groups showed a decline in the serum urea level, 
which fell by a mean of 36% in the CAVH group 
(p = 0.02) and 39% in the CVVH group (p = 0.005). 
Creatinine concentration declined by 19% in the 
CAVH group (p = no significant difference) and by 
33% in the CVVH group (p = 0.003) over the first 
3 days of treatment. In contrast, the PD population 
demonstrated a slight rise in both parameters over 
the same time course (p = no significant difference). 
The percent decreases in serum urea content for the 
CAVH and CVVH groups were significant when 
compared with the percent change in the PD group 
(p = 0.001), and again no significant difference 
existed between the two forms of hemofiltration. 
The total number of filters used was similar 
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Table IIIB. Details of age, lesion operation, and inotropic support for patients undergoing PD 
Cardiac Inotrop& drugs 
Age lesion Operation ( pg/kg/min ) 
4.5 yr Pulm. atresia, VSD, TGA prior L-R BTS Fontan DOP 20/EPI 0.3 
3.5 yr Univent. heart, L-TGA, VSD, sub-PS Fontan DOP 6.5 
N Ao atresia, VSD Repair VSD, PDA ligation, LV-Ao conduit DOP 30/NOR 0.4/EPI 0.1/DOB 15 
N Coarctation, VSDs Subclavian flap 
3.5 yr DILV, VSD, TGA Fontan DOP 20/EPI 0.2 
11 yr TAPVR, single atrium, PS Fontan, RPA repair DOP 5 
N TGA, VSD PA band, Blalock-Hanlon DOP 20/ISP 0.04/EPI 0.2 
N TGA, VSD, ASD, coarctation Coarctation repair, PDA ligation DOP 15/EPI 0.4 
N DORV, coarctation Coarctation and arch repair 
N Coarctation, VSD Coarctation repair DOP 20/EPI 0.7 
3.5 yr DIRV, PS, AS, sub-PS Fontan DOP 15/EPI 0.2 
N HLHS Norwood EPI 1.0/DOP 5/AMR 15 
2 mo VSDs, ASD, Vent. arrhyth. Repair ASD, VSD, PDA ligation DOP 10 
1 mo AVSD AVSD repair, PDA ligation DOP 7.5/EPI 0.3 
N Pulm. atresia with IVS PA-Ao shunt, patch RVOT DOP 5 
3 mo TGA, VSD PA band, BTS AMR 20/EPI 0.3/DOP 5 
N Ao atresia, VSD, PFO Arch repair, closure VSD, PFO, PDA DOP 10/ISP 0.2/AMR 15 
N TGA, VSD Switch, VSD repair AMR 15/DOP 20/DOB 50/EPI 0.5 
N HLHS Norwood DOP 15/EPI 0.1 
2 yr DILV, VA discordance Fontan DOP 5/DOB 25/EPI 1.0 
N HLHS Norwood DOP 10 
PD, Peritoneal dialysis; VSD, ventricular septal defect; TGA, transposition f the great arteries; PS, pulmonary stenosis; Ao, aortic; L-R BTS, left-to-right 
Blalock-Taussig shunt; DILV, double-inlet l ft ventricle; TAPVR, total anomalous pulmonary venous return; ASD, atrial septal defect; DIRV, double-inlet 
right ventricle; AS, aortic stenosis; HLHS, hypoplastic left heart syndrome; AVSD, atrioventricular septal defect;/'VS, intact ventricular septum; PFO, patent 
foramen ovale; VA, ventriculoatrial; PDA, patent ductus arteriosus; RPA, right pulmonary artery; PA, pulmonary artery; RVOT, right ventricular outflow tract; 
DOP, dopamine; EPI, epinephrine; NOR, norepinephrine; DOB, dobutamine; ISP, isoproterenol; AMR, amrinone; N, newborn. 
between the CAVH and CVVH populations. The 
patients undergoing CAVH required an average of 
2.6 filters during treatment, whereas an average of 
2.9 filters were used in the patients undergoing 
CVVH. However, because the therapy lasted longer 
in the CVVH group, the average cost of filters per 
patient-day was less. At an average filter cost of $40, 
the cost for filters per patient-day was $43 for those 
children undergoing CAVH and $23 for those man- 
aged with CVVH. 
Several electrolyte and hematologic abnormalities 
were common to all forms of renal replacement 
therapy (Table V). Hypokalemia nd hypophos- 
phatemia were experienced by the majority of indi- 
viduals, regardless of which renal replacement ther- 
apy they received. Additionally, many patients in 
each group had a fall in platelet count after the 
institution of therapy. The development of hypother- 
mia, with temperatures recorded at 34.5 °to 36 ° C, was 
seen only in the patients receiving CVVH. Other 
complications recorded were as follows: in PD, failure 
of dialysate drainage in three patients, peritonitis in 
two patients, increasing chest tube losses in two pa- 
tients and hyperglycemia in one patient. Hemorrhage 
was recorded for two patients undergoing CAVH and 
Table IV. Values before and after therapy for 
caloric intake expressed aspercent change from 
baseline before therapy 
PD CA VH C VVH 
Calories (kcal/kg) 
Pre 24.2 ± 2.42 13.5 + 1.85 20.5 + 5.2 
Post 32.4 ± 3.7 79.5 ± 15.6 76.4 ± 5.0 
% change 42.8 + 12.3 515 ± 130 409 4- 110 
Urea (mmol/L) 
Pre 17.4 + 2.5 22.5 + 2.42 25.5 ___ 3.7 
Post 18.1 ± 2.0 13.5 -+ 2.37 14.2 __+ 1.83 
% change 21.5 ± 13.5 -36.4 _+ 11.3 -39.2 --- 7.0 
Creatinine (p~mo[/L) 
Pre 184.5 __+ 22.3 162 + 43.0 205.2 + 14.8 
Post 194.1 + 18.0 122 + 30.7 136.6 + 13.4 
% change 16.6 + 9.1 -18.8 ± 15.2 -33.4 ± 4.4 
Values are mean ~+ standard error of the mean. 
limb ischemia for one. Superior vena caval thrombosis 
complicated the course of one patient having CVVH. 
Diseussion 
This study confirms the previously reported high 
mortality in patients with acute renal failure requir- 
ing renal replacement herapy after cardiopulmo- 
nary bypass. The objective of renal replacement 
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therapy is to interrupt he cycle of fluid retention 
and tissue edema, which if not reversed rapidly 
spirals downhill to death from sepsis and multiorgan 
failure. In addition, a successful management s rat- 
egy for these patients demands that the issue of the 
continuing negative nitrogen balance be addressed. 
Although PD can be effective in removing fluid, 
poor perfusion of the peritoneal membrane or leak- 
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age around the catheter site rarely results in removal 
of enough free water to allow for adequate alimen- 
tation. The advantage of the hemofiltration tech- 
niques is that they allow for greater control of fluid 
balance, which is dependent only on the hydrostatic 
pressure gradient in the case of CAVH and inde- 
pendent of hydrostatic pressure in the case of 
CVVH. In the 42 patients studied in this series, 
volume overload and tissue edema were a major 
problem, in part because of the inevitable fluid 
retention associated with cardiopulmonary b pass as 
well as a persisting low cardiac output state. The 
objective of achieving a large negative fluid balance 
was more consistently realized in the hemofiltration 
groups than in the PD group. Although the average 
fluid deficit per hour was greater in the CAVH 
group, more patients in the CVVH group reached a
goal of net negative fluid balance. This reflected the 
need to give fluid boluses to those patients treated 
by CAVH to maintain hemodynamic stability. It has 
been suggested that removal of this excess fluid in 
the immediate postoperative period may positively 
influence the patient's hemodynamic and ventilatory 
statusJ 9'31 More important, this tight control of 
fluid balance allowed for a large calorie intake and a 
positive nitrogen balance in the patients managed 
with hemofiltration compared with the modest in- 
creases in those managed with PD. The importance 
of maintaining a high calorie intake in patients with 
oliguric renal failure after surgical procedures was 
demonstrated in a recent study by Bartlett and 
associates, 32in which energy expenditure was mea- 
sured by indirect calorimetry. Those patients who 
had a positive energy balance (positive calorie bal- 
ance) had a significantly lower mortality than pa- 
tients with a negative nergy balance (9.4% versus 
37.5%). Finally, in this study with urea and creati- 
nine used as markers of solute clearance in renal 
replacement therapy, both forms of hemofiltration 
were shown to be more effective than PD. 
Several trends were evident from the demo- 
graphic data gathered in this series. First, the pa- 
tients in the hemofiltration groups tended to be 
older than those in the PD group. This is most likely 
a reflection of the need to establish additional 
vascular access in the hemofiltration groups, and 
this is at best difficult to achieve in young patients, 
leading to the bias of selecting older patients for this 
treatment who may have easier vascular access. 
However, both hemofiltration groups included 
young patients (<4 weeks of age) who successfully 
underwent this form of renal replacement therapy. 
Table V. Comparison of complications for each 
form of renal replacement therapy 
PD CA VII C FVH 
Complication No. % No. % No. % 
Hypokalemia 13 76 7 87 5 55 
(K + <3.5 mmol/L) 
Hypophosphatemia 11" 92 8 100 9 100 
(PO 4 < normal ower 
limit) 
Thrombocytopenia 5 29 4 50 3 33 
(fall to <50,000 × 
109~) 
Hypothermia 0 0 0 0 4 44 
(core temp. <36 °C) 
*Data available on 12 patients. 
Second, there was a difference in the time to initia- 
tion of renal replacement therapy. PD was started 
earlier than CAVH or CVVH, possibly reflecting a
hesitation to embark on a newer form of renal 
replacement therapy being introduced to the pedi- 
atric ICU, combined with the aforementioned need 
to obtain additional vascular access. When using 
CVVH in infants, we found that the preferred site of 
vascular access for the double-lumen catheter was in 
the right internal jugular vein with the tip advanced 
to the right atrium, which provided excellent flow 
with little resistance. In older children adequate 
flows could be achieved with the catheter placed in 
the inferior vena cava via the femoral vein. Finally, 
the patients in all three groups appeared to have a 
similar severity of illness, the vast majority requiring 
inotropic support, and many in all three groups 
required two or more inotropic drugs. However, 
postoperative sepsis was less prevalent in the PD 
group. These patients were in the pediatric ICU for 
a shorter time before starting dialysis, and it is 
recognized that prolonged stays in the ICU with 
multiple lines leads to an increased risk of infection. 
The complications encountered in all three pa- 
tient populations were similar. Although electrolyte 
changes, bleeding, and thrombosis are most likely 
directly attributable in large part to the renal re- 
placement therapy, the thrombocytopenia seen was 
probably due to multiple causes and has been pre- 
viously reported to be associated with acute renal 
failure after corrective cardiac operations in chil- 
dren. 5 Besides renal replacement therapy, other 
causes of thrombocytopenia include sepsis and 
platelet consumption and destruction on intracar- 
diac patches and valves. Hypothermia was identified 
as a problem in the CVVH group, but this problem 
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was eliminated after institution of a blood warmer in 
the return limb of the CVVH circuit. One case of 
vascular thrombosis was identified in the CVVH 
group, which may have resulted from a previously 
placed central ine. We did not routinely perform 
ultrasonic examinations onthe venous access ites to 
look for thrombus, because we anticipated that the 
high flow of heparinized blood would make intra- 
vascular clot formation unlikely. Obviously this be- 
comes an important issue for patients undergoing 
cavopulmonary shunts or Fontan procedures, of 
whom there were three in our series. 
When the efficacy and complications of the two 
forms of hemofiltration are compared, CVVH ap- 
pears to have distinct advantages over CAVH. The 
ability of the physician to exercise precise control 
over fluid balance by using pumped control of all 
input and output (except urine and insensible 
losses) in the former system ay have led to a higher 
hemodynamic stability of the CVVH group and a 
lower need for extra boluses of volume. This con- 
sideration, combined with the additional arterial 
access needed for CAVH and the documented 
short- and long-term problems resulting from this 
access in children, 33 has led to CVVH being 
adopted as the primary hemofiltration method. Ad- 
ditionally, the filter cost was less in the CVVH group 
and filter clotting was reduced in the artificially 
pumped circuit. Although this series is too small for 
any comparison of outcomes to be done, it is worth 
noting that in a recent randomized study that com- 
pared outcomes in adult patients with acute renal 
failure between pumped and nonpumped forms of 
hemofiltration, the survival was significantly better 
in the former (29% versus 13%). 34 
Despite the fact that both CAVH and CVVH 
have been successful in achieving fluid removal, 
improving biochemical status, and allowing for 
higher caloric intake, we have not been able to 
significantly reduce mortality from acute renal fail- 
ure. This may reflect a certain reluctance toinstitute 
early and aggressive treatment. Two recent studies 
have appeared in the literature citing lower mortal- 
ity rates than the generally quoted 50% to 70% for 
patients with acute renal failure requiring renal 
replacement therapy after cardiac operations. Book 
and associates 13 reported on a group of 15 patients 
managed with early institution of high-volume rap- 
idly cycled PD with a mortality rate of 33%, and 
Zobel and colleagues 19 reported on 11 patients 
treated with the early institution of CAVH or slow 
continuous ultrafiltration i  whom the mortality rate 
was 28%. In both groups all patients began receiving 
renal support within 48 hours of the operation and 
possibly during a period of renal insufficiency rather 
than overt renal failure. A recent report from Mee 31 
supports the notion of early institution of therapy to 
improve renal perfusion and decreased fluid over- 
load, particularly in patients with right-sided failure 
with the use of a PD catheter placed at the time of 
the operation and used initially as a device to drain 
abdominal fluid. In the presence of oliguria resistant 
to diuretics or hyperkalemia, the system is changed 
to dialysis with brief cycles and modest volumes of 
PD fluid (10 ml/kg). These studies together with our 
results suggest hat earlier intervention and more 
aggressive treatment of fluid overload and nutri- 
tional depletion may result in a decrease inmortality 
in acute renal failure. 
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